What Sofia Vergara's Case Reveals About IVF's Legal Gray Areas
Couples who create IVF embryos together should consider hiring lawyers before beginning the fertility treatment process, according to reproductive law experts. While unpleasant, much like a prenup, the process can help avoid a messy, complicated legal battle like the “custody” lawsuit against actress Sofia Vergara by her ex-fiancé, Nick Loeb. Few couples take this extra step before attempting IVF. But Vergara and Loeb’s case underscores the need for conscientious couples to prepare for every potential future scenario, no matter how unlikely, said San Diego-based surrogacy lawyer Stephanie Caballero. Couples already sign consent forms that detail how an IVF lab should distribute embryos in cases of death, divorce and other scenarios, but those forms are an agreement between two parties: the couple and the IVF clinic, not between the partners themselves, explained Caballero, an executive board member of the American Society for Reproductive Medicine’s legal professional group. Couples who want to guard against any future ambiguity should also hire individual lawyers to hammer out an agreement between themselves, she says. Caballero estimates that hiring lawyers for each partner would add $1,300 to $1,500 to the total cost of IVF, which averages $12,400. “Would it cost you an extra $1,000 to hire a separate attorney? Yes. One would draft, and the other would review it with [you],” said Caballero, who is...
ConclusionThis endoscopy-based study revealed the most common histology of benign SB tumors were hamartoma and adenoma, and malignant ones were lymphomas, GISTs, adenocarcinomas and metastatic cancers. Most of them were male gender, except for GISTs, and with proximal location, except for lymphomas. Further large-scale investigation efforts are warranted to elucidate the epidemiology of SB tumors.
ConclusionsThese findings linked the anti-tumor properties of PE with the immune microenvironment to present a reliable basis for the future practical application of PE in cervical cancer as a novel and pharmacologically safe immunotherapy strategy.Graphical abstract
ConclusionsThe experimental results from the pharmacological research enable the validation of their traditional uses in several of the groups of diseases in the countries of origin and reveal these plants to be a valuable source for therapeutic molecules. However, more toxicity assays and clinical trials would be necessary to establish optimal and safe doses of consumption on the application of these medicinal plants.Graphical abstract
In conclusion, this study makes clear that lncRNA THOR is up-regulated in retinoblastoma, and its over-expression significantly enhances the malignant phenotype transformation of retinoblastoma cells through up-regulating c-myc expression via enhancing its combination with TGF2BP1 protein. Overall, our study illustrates that lncRNA THOR/c-myc molecular cascade might be another potent target for retinoblastoma treatment.
Conclusions: AEE protected against 5-Fu-induced intestinal mucositis (IM) in mice through mechanisms that involved in promoting the enterocyte proliferative activity, maintaining the integrity of tight junction proteins, inhibiting oxidative stress and ameliorating the inflammatory disturbances. Accordingly, A. agallocha may be a promising therapeutic candidate used for the prevention of IM during cancer chemotherapy.Graphical abstractThe results of this study gave a scientific support for the protection of AEE on 5-Fu-induced IM in mice through mechanisms that involved in promoting the enterocyte proliferative activity, m...
Publication date: Available online 18 June 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Kian J. Rahbari, Jason D. Nosrati, Tanya M. Spektor, James R. Berenson
ConclusionAlthough patients with MYC-R lymphoma have been reported to be at high risk of primary treatment failure, this was not predicted by iPET+ results. Thus, the iPET result should not be used to guide changes in front-line or consolidative therapy for these patients.
Publication date: Available online 20 July 2018Source: Cancer EpidemiologyAuthor(s): E.E. Jedy-Agba, E.O. Dareng, S.N. Adebamowo, M. Odutola, E.A. Oga, F. Igbinoba, T. Otu, E. Ezeome, F. Bray, R. Hassan, C.A. Adebamowo
Publication date: Available online 20 July 2018Source: Cancer GeneticsAuthor(s): Daja Šekoranja, Emanuela Bostjančič, Vladka Salapura, Blaž Mavčič, Jože PižemAbstractAneurysmal bone cyst (ABC) is a benign but locally aggressive, mostly pediatric neoplasm, with characteristic USP6 gene rearrangement that distinguishes it from a secondary ABC and other primary bone tumors. With the advent of next-generation sequencing (NGS) technology, several hitherto unknown USP6 fusion partners have been identified in ABC. Accordingly, we present a case of an 18-year-old male with a solid sub-periosteal primary ABC in the di...
How well do you understand skin cancer risks? Test yourself with our latest quiz, and learn about USPSF recommendations for skin cancer prevention.